Stacey Johnson
Stacey Johnson is the editor of Signals and a contributor. For 25 years, Stacey has been providing strategic communications counsel to government, corporate, technology and health organizations. She began her career at the CTV Television Network and then moved to Hill & Knowlton Canada where she advised clients in a variety of industries and sectors. Stacey is the Vice President, Communications and Marketing for CCRM, a leader in developing and commercializing regenerative medicine-based technologies and cell and gene therapies. She has a Master's degree in Public Relations. You can follow her on Twitter @msstaceyerin.
Posts by: Stacey
Right Turn: Holiday science gifts, real and imagined
Kudos to the clever team at Venair for coming up with the following post on their LinkedIn page: Although I’m tempted to discuss this from a public relations/marketing lens, instead I’m adding these to the list of great gift ideas for the scientist or science lover in your life. If only these were real! (But […]
Right Turn: A patient’s perspective on living through cancer, and treatment progress
Do you remember the column “Life, Interrupted” by cancer patient Suleika Jaouad? She was 22 when she was diagnosed with acute myeloid leukemia (AML) and a rare blood disorder called myelodysplastic syndrome. With her hopes to be a war correspondent on hold (dashed?), she channelled her thoughts and fears and experiences of being a cancer […]
Right Turn: Blue Rodeo is aging like the rest of us
Blue Rodeo is an iconic Canadian band that performs “countrified rock” and has been around for four decades. It has received multiple awards and accolades, including being inducted into the Canadian Music Hall of Fame, and lead singers/songwriters Jim Cuddy and Greg Keelor were named Officers of the Order of Canada. I’ve been a fan […]
From the CDMO blog archives: Downstream processing
In 2019, CCRM launched a new blog to explain products, processes, terms, technologies, techniques and much more related to developing and manufacturing cell and gene therapy products. As a contract development and manufacturing organization (CDMO), CCRM wanted to share its knowledge with the global community. Fast forward to 2023 and CCRM is retiring the CDMO […]
Comments